ArticleNuclear medicine communications2025
Predictive factors for the efficacy of radioiodine therapy in patients with Graves' disease.
Article in Nuclear medicine communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Non-linear association between thyroid scintigraphy-derived thyroid weight and I-131 treatment efficacy in graves' disease: a multicenter restricted cubic spline and threshold analysis.Frontiers in endocrinology · 2026Article
- Preliminary volume-based optimization of radioactive iodine dose without radioactive iodine uptake in Graves' disease.Frontiers in endocrinology · 2026Article
- A prognostic nomogram model for non-complete remission following initial radioiodine therapy in Graves' hyperthyroidism.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe primary treatments for Graves' disease include antithyroid drugs (ATD), thyroidectomy, and iodine-131 (I-131) therapy. This study aimed to identify factors predicting treatment outcomes and the treatment period required to achieve euthyroidism after I-131 administration.
methodsThis study included 109 patients with Graves' disease who underwent I-131 therapy. Patients achieving euthyroidism or hypothyroidism within 1 year were classified as the success group, whereas those with remaining hyperthyroidism were classified as the failure group. Thyroid volume, computed tomography (CT) values, 24-h radioiodine uptake, effective half-life, the levels of free triiodothyronine, free thyroxine, thyroid-stimulating hormone, and thyrotropin receptor antibody, history of I-131 therapy, history of ATD use, history of potassium iodide use, and thyroid absorbed dose were analysed.
resultsLarger thyroid volume [odds ratio = 0.982, 95% confidence interval (CI): 0.967-0.998, P < 0.05] was identified as a predictive factor for treatment failure, as determined by multivariable logistic regression. In contrast, a shorter treatment period was associated with lower thyroid volume (hazard ratio = 0.990, 95% CI: 0.982-0.999, P < 0.05), higher thyroid absorbed dose (hazard ratio = 1.007, 95% CI: 1.002-1.011, P < 0.01), and lower thyroid CT values (hazard ratio = 0.963, 95% CI: 0.939-0.987, P < 0.01), as identified by multivariable Cox regression.
conclusionLarger thyroid volume was associated with treatment failure. Smaller thyroid volume, higher thyroid absorbed dose, and lower thyroid CT values were significant predictors of the treatment period required to achieve euthyroidism after I-131 administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.